Multi-cancer early detection company Grail, Inc. is now the target of a securities fraud class action lawsuit. This follows the company's announcement that its pivotal NHS-Galleri trial failed to meet its primary endpoint, causing its share price to collapse by more than 50%. The deadline for investors to apply to serve as the lead plaintiff is August 4, 2026.
Legal Action Officially Commenced
The lawsuit has been filed in the United States District Court for the Northern District of California. It seeks to represent investors who purchased Grail common stock between May 13, 2025, and February 19, 2026. The defendants, which include the company and certain executives, are accused of violating federal securities laws by making allegedly false and misleading statements regarding the prospects of the NHS-Galleri trial and the likelihood of achieving its primary endpoint.
Stock Crash Following Trial Results
On February 19, 2026, Grail announced that its key NHS-Galleri trial did not meet the primary endpoint of "observed statistically significant reduction in stage III-IV cancers." The company partly attributed this outcome to the possibility that a longer follow-up period might be needed to adequately compare the study groups.
Following this news, Grail's stock price plummeted from a closing price of $101.53 on February 19 to $50.21 on February 20, a single-day drop of approximately 50.55%. This wiped out more than half of the company's market value. Several analysts swiftly cut their price targets. Baird reduced its target by over 27% to $31, while Canaccord Genuity lowered its target from $105 to $80.
Central Allegations of the Lawsuit
The complaint alleges that throughout the class period, the defendants presented overwhelmingly positive statements to investors while concealing material adverse facts about the trial's true status. Specifically, it claims the company failed to disclose that the trial, conducted over a three-year follow-up period, was insufficient to demonstrate a reduction in stage III-IV cancers was achievable. It further alleges the trial duration was evidently inadequate to verify whether the primary endpoint could be met. The company is also accused of repeatedly refusing to provide detailed top-line results or other data, potentially concealing known unfavorable trends.
According to the filing, the defendants repeatedly told investors the trial was specifically designed to deliver significant results within three years. However, upon disclosure in February 2026, the company's CEO acknowledged that "a longer follow-up time may be needed." Analysts from Morgan Stanley, Canaccord Genuity, and Wolfe Research, who had built their models and price targets based on assurances from company management during the class period, were forced to make substantial revisions after the trial failed.
Options for Affected Investors
Several law firms have issued notices advising potentially affected investors about the case. The deadline to apply for lead plaintiff status is August 4, 2026. These legal representatives typically work on a contingency fee basis, meaning shareholders do not have to pay any upfront costs.
Comments